CNW Stock Overview
co.don AG, a biopharmaceutical company, develops, produces, and markets biopharmaceutical products for joint preservation and the regenerative treatment of articular cartilage defects worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
co.don AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.24 |
| 52 Week High | €1.93 |
| 52 Week Low | €0.24 |
| Beta | 1.46 |
| 1 Month Change | 0% |
| 3 Month Change | -28.99% |
| 1 Year Change | -84.49% |
| 3 Year Change | -93.45% |
| 5 Year Change | -98.48% |
| Change since IPO | -99.60% |
Recent News & Updates
Recent updates
Here's Why co.don (ETR:CNW) Can Afford Some Debt
Oct 06
Health Check: How Prudently Does co.don (ETR:CNWK) Use Debt?
May 06Will co.don (ETR:CNWK) Spend Its Cash Wisely?
Mar 15Analysts Expect Breakeven For co.don AG (ETR:CNWK) Before Long
Feb 08co.don's(ETR:CNWK) Share Price Is Down 85% Over The Past Three Years.
Jan 04
Shareholder Returns
| CNW | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -4.3% | -2.5% |
| 1Y | -84.5% | -19.4% | -0.4% |
Return vs Industry: CNW underperformed the German Biotechs industry which returned -23.4% over the past year.
Return vs Market: CNW underperformed the German Market which returned 4.7% over the past year.
Price Volatility
| CNW volatility | |
|---|---|
| CNW Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CNW's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine CNW's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 134 | Tilmann Bur | www.codon.de |
co.don AG, a biopharmaceutical company, develops, produces, and markets cell-based pharmaceutical products for joint preservation and the regenerative treatment of articular cartilage defects worldwide. It offers Spherox, a three dimensional chondrocyte product that is used to treat cartilage defects in adult knee joints; and co.don chondrosphere for the treatment of cartilage defects in the hip, ankle, shoulder and elbow, and knees of younger patients. The company serves accident and orthopedic surgeons.
co.don AG Fundamentals Summary
| CNW fundamental statistics | |
|---|---|
| Market cap | €6.55m |
| Earnings (TTM) | -€14.12m |
| Revenue (TTM) | €9.84m |
0.7x
P/S Ratio-0.5x
P/E RatioIs CNW overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CNW income statement (TTM) | |
|---|---|
| Revenue | €9.84m |
| Cost of Revenue | €1.88m |
| Gross Profit | €7.96m |
| Other Expenses | €22.09m |
| Earnings | -€14.12m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.53 |
| Gross Margin | 80.89% |
| Net Profit Margin | -143.55% |
| Debt/Equity Ratio | 64.1% |
How did CNW perform over the long term?
See historical performance and comparison